A way to enrich the rat hepatic cancer stem cells
Xing Wang(Guiyang Medical University), Dou Ke-feng(Xijing Hospital), Tao Wang(Pfizer (United States)), Ning Xia(Johannes Gutenberg University Mainz), Jiandong Yang(National Institute on Aging), Ge Zhao(Xijing Hospital), Weihui Liu(Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital), Nan You(Sun Yat-sen University), Zhen-bin Gong(Xijing Hospital), Ru Ji(Air Force Medical University)
Cited by 0
Related Papers
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2017|1.2k
c-Myc-Mediated Epigenetic Silencing of MicroRNA-101 Contributes to Dysregulation of Multiple Pathways in Hepatocellular Carcinoma
|Hepatology|2013|163
Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial
|The Lancet Respiratory Medicine|2019|139
Canonical notch pathway protects hepatocytes from ischemia/reperfusion injury in mice by repressing reactive oxygen species production through JAK2/STAT3 signaling
|Hepatology|2011|118
Long Non-coding RNA URHC Regulates Cell Proliferation and Apoptosis via ZAK through the ERK/MAPK Signaling Pathway in Hepatocellular Carcinoma
|International Journal of Biological Sciences|2014|111